Cancer Genetics Inc. (NASDAQ:CGIX) shares rose 3.5% during mid-day trading on Wednesday . The company traded as high as $2.39 and last traded at $2.38, with a volume of 88,739 shares trading hands. The stock had previously closed at $2.30.

Separately, Zacks Investment Research lowered shares of Cancer Genetics from a “buy” rating to a “hold” rating in a research note on Friday, July 29th.

The stock’s 50-day moving average price is $2.10 and its 200 day moving average price is $2.31. The company’s market cap is $38.37 million.

Cancer Genetics (NASDAQ:CGIX) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.05. The business earned $7 million during the quarter, compared to analysts’ expectations of $6.50 million. During the same period in the previous year, the business posted ($0.51) EPS. The company’s revenue for the quarter was up 67.3% compared to the same quarter last year. Equities research analysts expect that Cancer Genetics Inc. will post ($1.19) earnings per share for the current fiscal year.

In other Cancer Genetics news, Director John Pappajohn acquired 45,000 shares of the stock in a transaction dated Tuesday, August 16th. The stock was acquired at an average price of $2.29 per share, with a total value of $103,050.00. Following the completion of the purchase, the director now owns 2,287,109 shares in the company, valued at approximately $5,237,479.61. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.